• Conference Proceeding

Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation

Citation

Benson, C., Chirila, C., Graham, J., Radder, C., Zheng, Q., & Woodruff, K. (2015). Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. In [18], pp. A119–A119. .

Abstract

Clinical trial PSY-3012 was a randomized, multicenter, double-blind, parallel-group, relapse-prevention study of paliperidone palmitate 3-month injection (PP3M) versus placebo. Adults with schizophrenia received a once-monthly injection (PP1M) in an open-label (OL) 17-week transition phase, then a single PP3M injection for OL 12-week maintenance. Stabilized subjects were then randomized to PP3M or placebo in the double-blind (DB) phase. Exploratory objectives were to compare health resource utilization (HRU) and costs between PP3M and placebo.